The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting.
Giorgio Mustacchi
Honoraria - Agendia; Celgene; GlaxoSmithKline; Novartis; Pierre Fabre Medicament; Roche; Sanofi
Research Funding - Roche/Genentech; Sanofi
Annamaria Molino
Honoraria - Novartis
Elena Fiorio
No relevant relationships to disclose
Antonella Brunello
No relevant relationships to disclose
Vittorina Zagonel
Honoraria - Roche
Antonella Ferro
Honoraria - Novartis; Roche
Alessia Caldara
No relevant relationships to disclose
Aldo Iop
Honoraria - Amgen; Novartis; Roche
Salvatore Bonura
No relevant relationships to disclose
Micaela Stefani
Honoraria - Novartis; Roche
Research Funding - Pierre Fabre Medicament
Daniele Bernardi
Honoraria - AstraZeneca; Celgene
Research Funding - Pierre Fabre Medicament